The issuance of 17,366 new shares has been registered with the Norwegian Register of Business Enterprises. Following registration, the share capital of Photocure is NOK 13,313,693 divided into 26,627,386 shares, each with a par value of NOK 0.50. Each share represents one vote in the Company's general meeting.
For further information, please contact:
Photocure CFO Erik Dahl
Tel: +47 450 55 000
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com
This information is subject of the disclosure requirements of section 5-12 of the Norwegian Securities Trading Act.